

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Daix (France), Long Island City (New York), January 14, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of December 31, 2021:

- Cash: € 761,542.29
- Number of shares: 45,462

- Number of executions on buy side on semester: 1,253
- Number of executions on sell side on semester: 1,425
- Traded volume on buy side on semester: 209,935 shares for € 2,438,368.87
- Traded volume on sell side on semester: 211,076 shares for € 2,510,782.11

At the last half-year report as of June 30, 2021, the following resources were available in the liquidity account:

- Cash: € 689,129.05
- Number of shares: 46,603

- Number of executions on buy side on semester: 1,511
- Number of executions on sell side on semester: 1,435
- Traded volume on buy side on semester: 289,008 shares for € 3,547,633.77
- Traded volume on sell side on semester: 257,898 shares for € 3,208,144.47

When the contract was initially implemented, the following resources were included in the liquidity account:

- Cash: € 163,510.42
- Number of shares: 34,063

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	1,253	209,935	2,438,368.87	1,425	211,076	2,510,782.11
01/07/2021	-	-	-	25	4,000	47,320.00
02/07/2021	-	-	-	11	1,500	18,105.00
05/07/2021	6	2,500	29,750.00	-	-	-
06/07/2021	-	-	-	18	3,310	40,150.30
07/07/2021	15	4,500	53,370.00	18	3,474	41,965.92
08/07/2021	34	4,500	52,920.00	1	1	12.02
09/07/2021	7	672	7,788.48	1	1	11.76
12/07/2021	16	1,432	16,625.52	5	503	5,885.10
13/07/2021	4	896	10,304.00	11	1,229	14,305.56
14/07/2021	-	-	-	8	886	10,410.50
15/07/2021	4	1,459	16,793.09	7	1,713	20,350.44
19/07/2021	2	500	5,930.00	2	168	2,009.28
20/07/2021	10	1,000	11,830.00	5	500	5,950.00
21/07/2021	-	-	-	8	1,500	17,925.00
22/07/2021	1	1	12.00	27	2,527	30,728.32
23/07/2021	17	1,501	18,237.15	3	506	6,203.56
26/07/2021	47	4,499	53,358.14	-	-	-
27/07/2021	11	1,156	13,432.72	13	1,280	15,065.60
28/07/2021	14	1,386	16,008.30	1	1	11.64
29/07/2021	18	2,265	25,843.65	4	1,669	19,410.47
30/07/2021	5	500	5,680.00	5	501	5,711.40
02/08/2021	4	1,000	11,380.00	8	1,225	14,099.75
03/08/2021	44	6,852	75,988.68	2	1,000	11,130.00
04/08/2021	32	4,500	48,870.00	-	-	-
05/08/2021	54	7,000	72,310.00	-	-	-
06/08/2021	26	6,000	58,620.00	-	-	-
09/08/2021	16	2,500	23,750.00	-	-	-
11/08/2021	9	1,500	14,340.00	-	-	-
12/08/2021	16	1,300	12,233.00	-	-	-
13/08/2021	3	500	4,585.00	-	-	-
16/08/2021	-	-	-	1	70	658.00
17/08/2021	-	-	-	4	500	4,750.00
19/08/2021	-	-	-	4	500	4,900.00
20/08/2021	9	1,300	12,402.00	-	-	-
23/08/2021	-	-	-	15	1,248	12,367.68
24/08/2021	-	-	-	7	1,229	12,314.58
25/08/2021	-	-	-	8	2,023	20,594.14
26/08/2021	-	-	-	1	500	5,100.00

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	1,253	209,935	2,438,368.87	1,425	211,076	2,510,782.11
27/08/2021	7	500	5,050.00	17	2,592	26,723.52
30/08/2021	-	-	-	13	1,908	20,110.32
31/08/2021	-	-	-	30	4,600	50,232.00
01/09/2021	6	1,500	16,365.00	12	2,748	30,805.08
02/09/2021	29	1,000	11,080.00	11	2,752	31,042.56
03/09/2021	2	340	3,842.00	1	19	216.60
06/09/2021	1	160	1,808.00	6	981	11,212.83
07/09/2021	4	577	6,572.03	2	774	8,916.48
08/09/2021	3	244	2,781.60	9	1,000	11,530.00
09/09/2021	-	-	-	26	3,551	41,866.29
10/09/2021	13	2,000	23,360.00	-	-	-
13/09/2021	52	8,179	91,604.80	-	-	-
14/09/2021	-	-	-	15	1,500	16,875.00
15/09/2021	2	401	4,515.26	4	2,000	22,860.00
16/09/2021	-	-	-	4	1,000	11,590.00
17/09/2021	-	-	-	21	2,684	31,590.68
20/09/2021	5	1,500	17,625.00	23	3,316	39,360.92
21/09/2021	5	1,000	11,830.00	10	1,000	11,930.00
22/09/2021	-	-	-	41	6,500	80,925.00
23/09/2021	4	1,500	18,465.00	9	1,000	12,480.00
24/09/2021	15	5,000	60,400.00	18	2,500	30,900.00
27/09/2021	17	2,001	24,072.03	22	3,001	36,462.15
28/09/2021	9	2,000	24,060.00	7	1,500	18,345.00
29/09/2021	15	3,001	35,471.82	5	373	4,423.78
30/09/2021	4	499	5,818.34	11	3,127	37,430.19
01/10/2021	26	4,805	55,930.20	7	820	9,635.00
04/10/2021	4	1,500	17,265.00	5	510	5,946.60
05/10/2021	5	695	7,950.80	13	1,000	11,580.00
06/10/2021	13	2,501	28,411.36	9	500	5,780.00
07/10/2021	17	3,399	37,796.88	4	1,000	11,180.00
08/10/2021	16	3,100	33,728.00	9	2,000	22,060.00
11/10/2021	1	1	10.80	42	4,000	44,320.00
12/10/2021	-	-	-	52	6,576	75,689.76
13/10/2021	1	500	5,800.00	5	500	5,850.00
14/10/2021	6	1,500	17,415.00	2	500	5,880.00
15/10/2021	5	1,000	11,580.00	2	119	1,392.30
18/10/2021	10	2,000	22,920.00	9	500	5,800.00
19/10/2021	-	-	-	42	6,475	77,635.25

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	1,253	209,935	2,438,368.87	1,425	211,076	2,510,782.11
20/10/2021	13	1,626	19,430.70	3	1,000	12,340.00
21/10/2021	1	500	6,010.00	17	2,500	30,650.00
22/10/2021	6	1,001	12,242.23	14	1,500	18,615.00
25/10/2021	14	3,429	41,765.22	13	2,771	34,138.72
26/10/2021	6	2,000	24,940.00	46	6,729	84,650.82
27/10/2021	27	5,001	62,512.50	5	1,174	14,921.54
28/10/2021	3	1,001	12,442.43	12	2,406	30,219.36
29/10/2021	1	498	6,155.28	22	3,920	49,901.60
01/11/2021	5	501	6,412.80	7	1,000	12,980.00
02/11/2021	4	1,000	12,780.00	3	1,500	19,425.00
03/11/2021	21	3,823	48,513.87	-	-	-
04/11/2021	13	4,176	52,534.08	49	5,741	73,255.16
05/11/2021	26	5,570	68,789.50	-	-	-
08/11/2021	7	1,891	22,559.63	-	-	-
09/11/2021	5	1,483	17,499.40	56	6,222	76,095.06
10/11/2021	15	2,000	24,260.00	1	136	1,672.80
11/11/2021	25	4,600	57,224.00	53	4,957	62,160.78
12/11/2021	23	3,400	41,140.00	1	1	12.46
15/11/2021	19	2,500	29,650.00	3	1,000	11,880.00
16/11/2021	30	2,611	30,679.25	21	1,000	11,980.00
17/11/2021	9	1,489	17,227.73	2	500	5,850.00
18/11/2021	8	900	10,332.00	2	1,000	11,630.00
19/11/2021	30	2,774	31,817.78	8	2,613	30,336.93
22/11/2021	-	-	-	15	2,946	34,409.28
23/11/2021	1	20	233.20	23	2,996	35,742.28
24/11/2021	17	3,519	40,996.35	14	1,506	17,680.44
25/11/2021	1	6	70.20	30	3,958	47,218.94
26/11/2021	12	2,995	35,191.25	11	2,000	23,660.00
29/11/2021	-	-	-	21	2,643	31,478.13
30/11/2021	21	4,499	52,773.27	7	1,000	11,760.00
01/12/2021	-	-	-	29	3,857	46,014.01
02/12/2021	9	1,938	23,081.58	3	1,183	14,172.34
03/12/2021	7	2,562	30,308.46	7	1,183	14,172.34
06/12/2021	-	-	-	22	4,615	55,564.60
07/12/2021	3	500	6,030.00	13	2,000	24,480.00
08/12/2021	-	-	-	23	3,500	43,890.00
09/12/2021	9	3,000	36,240.00	13	1,500	18,225.00
10/12/2021	11	2,500	30,000.00	2	501	6,092.16

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	1,253	209,935	2,438,368.87	1,425	211,076	2,510,782.11
13/12/2021	13	1,500	17,715.00	13	2,000	23,860.00
14/12/2021	-	-	-	13	1,999	24,247.87
15/12/2021	16	2,000	24,040.00	-	-	-
16/12/2021	8	2,000	24,240.00	19	3,033	36,941.94
17/12/2021	2	500	6,030.00	2	468	5,709.60
20/12/2021	30	3,501	41,486.85	-	-	-
21/12/2021	5	1,499	17,403.39	7	1,099	12,847.31
22/12/2021	3	16	185.60	15	3,453	41,125.23
23/12/2021	10	1,484	17,644.76	7	2,454	29,619.78
24/12/2021	1	1	12.06	7	686	8,382.92
27/12/2021	12	2,999	36,437.85	15	1,807	22,298.38
28/12/2021	18	3,000	35,940.00	8	1,000	12,180.00
29/12/2021	8	2,000	23,620.00	5	1,518	18,140.10
30/12/2021	-	-	-	2	11	130.90
31/12/2021	4	500	5,880.00	-	-	-

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of preclinical programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained both FDA Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH. Lanifibranor is currently being evaluated in a pivotal Phase III clinical trial.

The Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases resulting in the discovery of the drug candidate cediogant (AABV-157), an oral ROR γ inverse agonist. Cediogant has reached clinical proof of concept during a Phase Ib clinical trial and is currently being evaluated in a Phase IIb clinical trial in patients with moderate to severe chronic plaque psoriasis. This collaboration enables Inventiva to receive payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from this collaboration.

Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial

evaluating odiparcil for the treatment of adult MPS VI patients in 2019 and received both FDA Fast Track and Rare Paediatric Disease designation for odiparcil in MPS VI.

In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.

Contacts

Inventiva

Pascaline Clerc
VP of Global External Affairs
media@inventivapharma.com
+1 240 620 9175

Brunswick Group

Laurence Frost /
Tristan Roquet Montegon /
Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Westwicke, an ICR Company

Patricia L. Bank
Investor relations
patti.bank@westwicke.com
+1 415 513 1284

Important Notice

This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva's clinical trials, clinical trial data releases, clinical development plans, milestone and royalty payments and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, with respect to the anticipated timeline for seeking of regulatory approvals for candidates, or that candidates will receive the necessary regulatory approvals. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory

approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2020 filed with the Autorité des Marchés Financiers on March 15, 2021, the Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 15, 2021, Amendment No. 1 to our Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 24, 2021, as well as the full-year financial report for the year ended December 31, 2020 for additional information in relation to such factors, risks and uncertainties.

Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.